Navigation Links
Intermittent androgen deprivation at least as effective as continuous androgen deprivation
Date:1/5/2010

Arnhem, December 2009 'Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature' is the title of an article by P-A. Abrahamsson in the January issue of European Urology, the official journal of the European Association of Urology. The author evaluates available evidence regarding the efficacy and tolerability of intermittent androgen deprivation (IAD) and assess its value in the treatment of prostate cancer (PCa).

Prostate cancer (PCa) is the second most common male cancer worldwide and the most frequently occurring in Europe (20.3% of the total in 2006). Androgen-deprivation therapy (ADT) has progressed since 1941 when surgical castration was shown to improve PCa outcomes. The well-known side effect profile of ADT has significant quality-of-life implications such as sexual dysfunction, hot flushes, fatigue etc. Furthermore, it appears that androgen suppression causes a change in stem cells from an androgen-dependent to an androgen-independent phenotype. Because this progression to androgen independence is thought to begin early after treatment initiation, stopping androgen deprivation prior to this change occurring should restore apoptotic potential and help tumour cells remain sensitive to re-initiating treatment.

The strategy behind IAD, therefore, is to alternate androgen blockade with treatment cessation, allowing hormonal recovery between treatment periods, thus potentially improving tolerability and quality of life.

The author wishes to evaluate available evidence regarding the efficacy and tolerability of IAD and assess its value in the treatment of PCa. Key phase 2/3 clinical trials of IAD in PCa published within the last 10 years were identified on Medline using different search terms.

The conclusions were that IAD seems to be as effective as continuous androgen deprivation while showing tolerability and quality of life advantages, especially recovery of sexual potency. IAD has been a treatment option for >20 years and the EAU considers that its status should no longer be regarded as investigational.

However, QoL data are surprisingly limited given that this, rather than survival, is the key driver for IAD and considering the length of time this approach has been under evaluation.

Based on available evidence and general clinical opinion, IAD is a valid treatment option in nonmetastatic PCa cases, i.e. patients with locally advanced disease with or without lymph node involvement and those experiencing relapse following curative treatment. These patients have a higher chance of survival than those with more advanced disease, making QoL a key consideration. Full results from phase 3 trials, which include both locally advanced and metastatic patients, will further clarify target populations.

IAD has come of age, and many clinicians believe it has earned its place in the management of PCa; however, there are still insufficient data to determine whether IAD has the potential to prevent or reverse the long-term complications associated with ADT.


'/>"/>

Contact: Lindy Brouwer
l.brouwer@uroweb.org
European Association of Urology
Source:Eurekalert

Related medicine news :

1. Meckels diverticulum masked by intermittent recurrent subocclusive episodes
2. New Analysis: Light and Intermittent Smokers Overlooked in Traditional Tobacco Research
3. Intermittent Catheter Market to Surpass 40% CAGR Between 2008 and 2012
4. Rochester Medical Applauds Improved U.S. Medicare Coverage Policy for Intermittent Catheters
5. BUSM researchers propose a relationship between androgen deficiency and cardiovascular disease
6. Protein that suppresses androgen receptors could improve prostate cancer diagnosis, treatment
7. Androgen Production Continues in Prostate Cancer Tumors
8. How advanced prostate cancer becomes resistant to androgen-deprivation therapy
9. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
10. Study shows that sleep deprivation can negatively affect information processing
11. Sleep Deprivation Might Lead to Alzheimers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... ... a biographical account following a man who went on to support his country and serve ... in Lynn Haven, Florida and at the age of 5, his family moved to Pensacola ... the Navy and got married right out of boot camp. , He and his ...
(Date:1/20/2017)... ... 20, 2017 , ... “Journey to Christmas:” a beautiful and enchanting tale that teaches children the ... a mother of three in Oklahoma City, and a devoted woman of faith. , ... has been in the back of my mind for years, but actually doing it might ...
(Date:1/19/2017)... ... ... Today, the Centers for Medicare & Medicaid Services (CMS) announced over 359,000 ... in 2017. Clinicians who participate in APMs are paid for the quality of care ... effort to build a system that delivers better care and one in which clinicians ...
(Date:1/19/2017)... ... 19, 2017 , ... With the cold weather here, many people will have to clear snow ... clearing large amounts of snow, but they can be dangerous when used incorrectly. That’s why ... Commission for the proper use of snow blowers:, , When removing ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... solutions, has recently unveiled impressive transportable capabilities with their iMedHD2™ Portable Teleultrasound ... an extension to RMT technology that delivers HD, dynamic, streaming ultrasound images and ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... WASHINGTON , Jan. 19, 2017 Conference Call and ... VNDA ) today announced it will release results for the ... market closes. ... Vanda will host a conference call at 4:30 PM ET on ... quarter and full year 2016 financial results and other corporate activities. ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 This ... the current and future scenario of the global market. ... rising opioid consumption. Severe chronic constipation is a major ... to traditional laxatives. Hence, novel targeted therapy has been ... OIC sufferers, launch of targeted medicines, and growing awareness ...
(Date:1/19/2017)... , Jan. 19, 2017  Stealth BioTherapeutics Inc. ( ... treat mitochondrial dysfunction, today announced new additions to its ... as Chief Medical Officer, and Daniel Geffken ... that Jim Carr , Pharm.D. has been promoted ... are pleased to welcome Doug and Daniel to our ...
Breaking Medicine Technology: